Silviu Itescu

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

VC-01-post-implant-final1-e1503703572933, viacyte

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Mesoblast (MSB) buys Osiris (OSIR) stem cell unit

The Australian stem cell biotech Mesoblast (MSB) has¬†reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, …

Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »